Deborah Stephens is a Hematology physician. OpenAlex indexes 348 publications with 5,476 citations (h-index 36); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2000 Circle Of Hope Dr
Salt Lake City, UT 841125550
Telephone
801-585-0236Provider last certified this registry record 14 Dec 2023.
Clinical trials
- Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors
Sponsor: UNC Lineberger Comprehensive Cancer Center
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20257 payments
- Lilly USA, LLCProgram year20251 payment
- BeOne Medicines USA, Inc.Program year202510 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2016–2023 per NIH RePORTER. The latest:
- Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
University of Utah
FY2023$83,830R50CA275929 - Novel Strategies to Eliminate Resistance to B-cell Receptor Inhibitor Therapy in Lymphoid Malignancies
University of Utah
FY2020$180,360K23CA212271 - Novel Strategies to Eliminate Resistance to B-cell Receptor Inhibitor Therapy in Lymphoid Malignancies
University of Utah
FY2019$180,360K23CA212271
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”